Pvg Asset Management Corp Cellectar Biosciences, Inc. Transaction History

Pvg Asset Management Corp

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 10, 2021	SELL	$8.2 - $12.4 $1.59 Million - $2.4 Million	-193,510 Closed	0 $0
Q2 2021 Aug 17, 2021	BUY	$11.8 - $18.2 $2.16 Million - $3.34 Million	183,350 Added 1804.63%	193,510 $2.3 Million
Q1 2021 May 14, 2021	BUY	$15.2 - $25.0 $154,432 - $254,000	10,160 New	10,160 $163,000

Ticker CLRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 6,114,290
Market Cap $9.17M
Description
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...

Get notified when there are updates to the investment portfolio of Pvg Asset Management Corp, based on Form 13F filings with the SEC.

Stay updated on Pvg Asset Management Corp with notifications on news.